Stay updated with breaking news from Genentech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patien
There are unique complexities when implementing bispecific antibodies, including site of care considerations, monitoring, and management of adverse events.
LEXINGTON, Mass., April 5, 2024 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April...
AUSTIN, Texas, April 05, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France. The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test.
Biotech Sector a Healthy Choice for Investors? (Nasdaq: ELTX) (Nasdaq: VRDN) (Nasdaq: KZIA) (Nasdaq: RGLS)